BioWorld3d
IL-21120033, CXCR7 agonist with significant efficacy in DSS-induced colitis model
Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.
Scientific Research Publishing17d
Shi, Y., Riese, D.J. and Shen, J. (2020) The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer. Frontiers in Pharmacology, 11, Article 574667.
ABSTRACT: The two known receptors, CXCR4 and CXCR7, for the chemokine stromal cell-derived factor-1 (SDF1) play a role in the development and metastasis of multiple cancers, including melanoma. CXCR4 ...
Scientific Research Publishing17d
Rossi, D. and Zlotnik, A. (2000) The Biology of Chemokines and Their Receptors. Annual Review of Immunology, 18, 217-242.
ABSTRACT: The two known receptors, CXCR4 and CXCR7, for the chemokine stromal cell-derived factor-1 (SDF1) play a role in the development and metastasis of multiple cancers, including melanoma. CXCR4 ...
C&EN20d
Design, Synthesis and Pharmacological Characterization of the First Photoswitchable Small-Molecule Agonist for the Atypical Chemokine Receptor 3
Division of Medicinal Chemistry, Amsterdam Institute of Molecular and Life Sciences, Faculty of Science, Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands ...
BioSpace25d
iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis
DONGTAN, KOREA, February 13, 2025 - iLeadBMS, a spin-off biotech from Ildong Pharmaceutical Group, announced that it has received a notification from the US Food and Drug Administration (FDA) that its ...